Zacks Research Has Optimistic Outlook of LABT Q3 Earnings

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) – Equities research analysts at Zacks Research increased their Q3 2026 EPS estimates for shares of Lakewood-Amedex Biotherapeutics in a report released on Wednesday, August 26th. Zacks Research analyst D. Bautz now forecasts that the company will post earnings of $0.81 per share for the quarter, up from their previous estimate of $0.56. The consensus estimate for Lakewood-Amedex Biotherapeutics’ current full-year earnings is $2.52 per share. Zacks Research also issued estimates for Lakewood-Amedex Biotherapeutics’ Q4 2026 earnings at $0.76 EPS and FY2026 earnings at $4.96 EPS.

A number of other analysts have also recently weighed in on LABT. Weiss Ratings assumed coverage on Lakewood-Amedex Biotherapeutics in a research note on Monday, July 20th. They issued a “sell (e-)” rating on the stock. Wall Street Zen lowered Lakewood-Amedex Biotherapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, Lakewood-Amedex Biotherapeutics currently has an average rating of “Sell”.

Lakewood-Amedex Biotherapeutics Stock Up 10.4%

NASDAQ LABT opened at $2.76 on Wednesday. The firm has a market cap of $6.54 million and a PE ratio of -0.58. The business’s 50 day moving average price is $2.49. Lakewood-Amedex Biotherapeutics has a 52 week low of $1.66 and a 52 week high of $98.20.

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) last issued its quarterly earnings results on Friday, August 14th. The company reported ($2.75) earnings per share for the quarter.

About Lakewood-Amedex Biotherapeutics

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.